Business
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, \"We are encouraged by these publications, and believe taken together they may provide a rationale for switching patients within the CD20 class prior to leaving the class, as well as the first anecdotal evidence of the success of such a strategy, as highlighted by the seven case reports in Frontiers in Immunology. The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an insightful look at the evolution of anti-CD20 treatments and a potential rationale as to why switching within the same class is a viable strategy. We remain committed to the MS community and believe these papers highlight the real-world impact BRIUMVI can have on the those living with MS and we will continue to study this phenomenon through our ongoing ENHANCE and ENABLE studies to assess if these anecdotal accounts can be further supported.” JOURNAL ARTICLES:Title: Switching to Ublituximab from Prior anti-CD20 Monoclonal Antibody Therapy: A Case Report Series The article describes a retrospective case series of seven individuals with multiple sclerosis (MS) treated in private practice or at an MS clinic who switched to ublituximab from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of each case, including clinical and/or radiological outcomes on initial anti-CD20 therapy, reasons for switching, and outcomes after starting ublituximab therapy are provided.This case series was published in Frontiers in Immunology and the online version of the publication can be accessed at Frontiers in Immunology. Title: The Evolution of Anti-CD20 Treatment for Multiple Sclerosis The article focuses on the unique characteristics of the anti-CD20...